Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs

In spite of the widespread use of lifestyle modifications programs, many patients with PCOS are obese and prevalence of obesity in PCOS remains high. In this study, we present the data on the use of semaglutide, an incretin mimetic drug, in obese PCOS patients who were unresponsive to a lifestyle mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmina, Enrico, Longo, Rosa Alba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531549/
https://www.ncbi.nlm.nih.gov/pubmed/37762862
http://dx.doi.org/10.3390/jcm12185921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531549/
https://www.ncbi.nlm.nih.gov/pubmed/37762862
http://dx.doi.org/10.3390/jcm12185921

Ejemplares similares